Gene A, a gene increased by mutant KRAS, is a potentially druggable target for lung adenocarcinoma

被引：0

作者：

Umeda, Kanna ^{[1
]}

Kawabe, Nozomi ^{[1
]}

Muraki, Nao ^{[1
]}

Komeda, Kazuki ^{[2
]}

Ohashi, Ayano ^{[1
]}

Katsuda, Masahito ^{[1
]}

Tomatsu, Aya ^{[1
]}

Yoshida, Mikina ^{[1
]}

Minna, John ^{[3
,4
]}

Tanaka, Ichidai ^{[2
]}

Morise, Masahiro ^{[2
]}

Matsushima, Miyoko ^{[1
]}

Kawabe, Tsutomu ^{[1
]}

Sato, Mitsuo ^{[1
]}

机构：

[1] Nagoya Univ, Div Host Def Sci, Dept Integrated Hlth Sci, Grad Sch Med, Nagoya, Aichi, Japan

[2] Nagoya Univ, Dept Resp Med, Grad Sch Med, Nagoya, Aichi, Japan

[3] Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA

[4] Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA

来源：

RESPIROLOGY | 2024年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

AP04-003

引用

页码：91 / 91

页数：1

共 50 条

[21] New monoallelic combination of KRAS gene mutations in codons 12 and 13 in the lung adenocarcinoma
Charkiewicz, R.
Niklinska, W.
Zalewski, G.
Charkiewicz, A.
Kozlowski, M.
Sulewska, A.
Chyczewski, L.
ADVANCES IN MEDICAL SCIENCES, 2013, 58 (01): : 83 - 89
[22] Lung adenocarcinoma-related target gene prediction and drug repositioning
Huang, Rui Xuan
Siriwanna, Damrongrat
Cho, William C.
Wan, Tsz Kin
Du, Yan Rong
Bennett, Adam N.
He, Qian Echo
Liu, Jun Dong
Huang, Xiao Tai
Chan, Kei Hang Katie
FRONTIERS IN PHARMACOLOGY, 2022, 13
[23] Adenylosuccinate Synthetase 1 Gene Is a Novel Target of Deletion in Lung Adenocarcinoma
Miller, Joshua C.
Blake, Daniel C., Jr.
Herzog, Christopher R.
MOLECULAR CARCINOGENESIS, 2009, 48 (12) : 1116 - 1122
[24] FoxO3a gene is a target of deletion in mouse lung adenocarcinoma
Herzog, Christopher R.
Blake, Daniel C., Jr.
Mikse, Oliver R.
Grigoryeva, Lubov S.
Gundermann, Erica L.
ONCOLOGY REPORTS, 2009, 22 (04) : 837 - 843
[25] Potential Role of TRAIL in Metastasis of Mutant KRAS Expressing Lung Adenocarcinoma
Pal, Shyama
Amin, Prayag J.
Sainis, K. B.
Shankar, Bhavani S.
CANCER MICROENVIRONMENT, 2016, 9 (2-3) : 77 - 84
[26] The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol
Albayrak, Gulsah
Korkmaz, Funda Demirtas
Tozcu, Duygu
Turacli, Irem Dogan
JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (06) : 10564 - 10571
[27] KRAS mutant lung adenocarcinoma is associated with distinct mutational signature profiles
Woodhouse, Laura
Hawari, Aliah
Gruber, Andreas
Lindsay, Colin
Wedge, David
CANCER RESEARCH, 2024, 84 (06)
[28] Flavopiridol's effects on metastasis in KRAS mutant lung adenocarcinoma cells
Turacli, Irem Dogan
Korkmaz, Funda Demirtas
Candar, Tuba
Ekmekci, Abdullah
JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (04) : 5628 - 5635
[29] Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma
Boiarsky, D.
Lydon, C. A.
Chambers, E. S.
Sholl, L. M.
Nishino, M.
Skoulidis, F.
Heymach, J., V
Luo, J.
Awad, M. A.
Janne, P. A.
Van Allen, E. M.
Barbie, D. A.
Vokes, N. I.
ANNALS OF ONCOLOGY, 2023, 34 (07) : 589 - 604
[30] Advancements in gene therapies targeting mutant KRAS in cancers
Wang, Yuhang
Bui, Thuy Anh
Yang, Xinpu
Hutvagner, Gyorgy
Deng, Wei
CANCER AND METASTASIS REVIEWS, 2025, 44 (01)

← 1 2 3 4 5 →